This guest blog post was provided by Healthline.com as part of their SEO Marketing effort. Merck Serono, a pharmaceutical company, has come to terms with the bankrupt company, Peptimmune, for exclusive rights to the PI-2301, an experimental multiple sclerosis drug. PI-2301 has already completed Phase I trials and is entering Phase II which is clinical [...]
-
Feedburner
enter your email to
receive notices of
new blog postsFBF ▪ Powered by ®Google Feedburner